From Seekingalpha · SA Transcripts · · 40s
Lexeo Therapeutics Discusses PKP2 Arrhythmogenic Cardiomyopathy Treatment Gap
Lexeo Therapeutics highlights unmet need in PKP2 arrhythmogenic cardiomyopathy with no approved treatments.
In brief
Lexeo Therapeutics highlights unmet need in PKP2 arrhythmogenic cardiomyopathy with no approved treatments. Lexeo Therapeutics states PKP2 arrhythmogenic cardiomyopathy has no approved treatments to modify its course. Originally reported by Seekingalpha.
Lexeo Therapeutics
Lexeo Therapeutics discusses clinical assessment and unmet need in PKP2 arrhythmogenic cardiomyopathy.
PKP2 Arrhythmogenic Cardiomyopathy
PKP2 arrhythmogenic cardiomyopathy is a serious progressive genetic disease with no approved treatment designed to modify its course.
Unmet Need
The affected population is larger than those associated with many traditional rare disease gene therapy.
In short
Lexeo Therapeutics states PKP2 arrhythmogenic cardiomyopathy has no approved treatments to modify its course.
